Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$25.85
0.080.31%
At close: -
$25.60
-0.25-0.97%
After Hours: 7:26 PM EDT
Comments
Loading...
Summit Therapeutics Analyst Ratings and Price Targets | NASDAQ:SMMT | Benzinga
Summit Therapeutics Inc has a consensus price target of $36.55 based on the ratings of 12 analysts. The high is $44 issued by Jefferies on April 25, 2025. The low is $30 issued by Evercore ISI Group on March 12, 2025. The 3 most-recent analyst ratings were released by Goldman Sachs, JMP Securities, and Jefferies on May 2, 2025, April 28, 2025, and April 25, 2025, respectively. With an average price target of $41.67 between Goldman Sachs, JMP Securities, and Jefferies, there's an implied 62.76% upside for Summit Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
JMP Securities
Jefferies
Citigroup
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Summit Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2025 | Buy Now | 60.16% | Goldman Sachs | Salveen Richter63% | $37 → $41 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 56.25% | JMP Securities | Reni Benjamin47% | $40 → $40 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/25/2025 | Buy Now | 71.87% | Jefferies | Kelly Shi58% | $31 → $44 | Maintains | Buy | Get Alert |
| 04/23/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt34% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2025 | Buy Now | 36.72% | Citigroup | Yigal Nochomovitz54% | $23 → $35 | Upgrade | Neutral → Buy | Get Alert |
| 03/21/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt34% | — | Initiates | → Overweight | Get Alert |
| 03/12/2025 | Buy Now | 17.19% | Evercore ISI Group | Cory Kasimov69% | → $30 | Initiates | → Outperform | Get Alert |
| 02/28/2025 | Buy Now | 64.06% | Goldman Sachs | Salveen Richter63% | → $42 | Initiates | → Buy | Get Alert |
| 02/25/2025 | Buy Now | 25% | Citizens Capital Markets | Reni Benjamin47% | $32 → $32 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/25/2025 | Buy Now | 71.87% | HC Wainwright & Co. | Mitchell Kapoor38% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 01/21/2025 | Buy Now | 71.87% | HC Wainwright & Co. | Mitchell Kapoor38% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 36.72% | Truist Securities | Asthika Goonewardene43% | → $35 | Initiates | → Buy | Get Alert |
| 12/11/2024 | Buy Now | 17.19% | Wells Fargo | Mohit Bansal68% | → $30 | Initiates | → Overweight | Get Alert |
| 12/06/2024 | Buy Now | 21.09% | Jefferies | Brent Thill77% | → $31 | Initiates | → Buy | Get Alert |
| 11/18/2024 | Buy Now | 71.87% | HC Wainwright & Co. | Mitchell Kapoor38% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 11/04/2024 | Buy Now | 25% | JMP Securities | Reni Benjamin47% | → $32 | Initiates | → Market Outperform | Get Alert |
| 10/31/2024 | Buy Now | 71.87% | HC Wainwright & Co. | Mitchell Kapoor38% | $45 → $44 | Maintains | Buy | Get Alert |
| 10/04/2024 | Buy Now | 75.78% | HC Wainwright & Co. | Mitchell Kapoor38% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | -10.16% | Citigroup | Yigal Nochomovitz54% | $19 → $23 | Downgrade | Buy → Neutral | Get Alert |
| 09/25/2024 | Buy Now | 56.25% | Stifel | Bradley Canino40% | $25 → $40 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 75.78% | HC Wainwright & Co. | Mitchell Kapoor38% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 75.78% | HC Wainwright & Co. | Mitchell Kapoor38% | $30 → $45 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | -25.78% | Citigroup | Yigal Nochomovitz54% | $13 → $19 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | -2.34% | Stifel | Bradley Canino40% | $14 → $25 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 17.19% | HC Wainwright & Co. | Mitchell Kapoor38% | $16 → $30 | Maintains | Buy | Get Alert |
| 09/03/2024 | Buy Now | -37.5% | HC Wainwright & Co. | Mitchell Kapoor38% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2024 | Buy Now | -37.5% | HC Wainwright & Co. | Mitchell Kapoor38% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2024 | Buy Now | -37.5% | HC Wainwright & Co. | Mitchell Kapoor38% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | -37.5% | HC Wainwright & Co. | Mitchell Kapoor38% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | -37.5% | HC Wainwright & Co. | Mitchell Kapoor38% | → $16 | Initiates | → Buy | Get Alert |
| 06/03/2024 | Buy Now | -45.31% | Stifel | Bradley Canino40% | $8 → $14 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | -49.22% | Citigroup | Yigal Nochomovitz54% | $7 → $13 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | -72.66% | Citigroup | Yigal Nochomovitz54% | → $7 | Initiates | → Buy | Get Alert |
| 03/26/2024 | Buy Now | -68.75% | Stifel | Bradley Canino40% | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Summit Therapeutics (SMMT) stock?
The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by Goldman Sachs on May 2, 2025. The analyst firm set a price target for $41.00 expecting SMMT to rise to within 12 months (a possible 60.16% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Summit Therapeutics (SMMT)?
The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by Goldman Sachs, and Summit Therapeutics maintained their buy rating.
When was the last upgrade for Summit Therapeutics (SMMT)?
The last upgrade for Summit Therapeutics Inc happened on March 26, 2025 when Citigroup raised their price target to $35. Citigroup previously had a neutral for Summit Therapeutics Inc.
When was the last downgrade for Summit Therapeutics (SMMT)?
The last downgrade for Summit Therapeutics Inc happened on September 27, 2024 when Citigroup changed their price target from $19 to $23 for Summit Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Summit Therapeutics (SMMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on May 2, 2025 so you should expect the next rating to be made available sometime around May 2, 2026.
Is the Analyst Rating Summit Therapeutics (SMMT) correct?
While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a maintained with a price target of $37.00 to $41.00. The current price Summit Therapeutics (SMMT) is trading at is $25.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
